Pacific Biosciences

PACB

Market cap $474M

Genomics gains momentum as breakthroughs, falling sequencing costs, and CRISPR advances drive precision medicine and fuel rapid market growth.

Pacific Biosciences of California (PACB) closed the most recent trading day at $1.44, moving +1.41% from the previous trading session.

PACB's strong Q4 results, expanding sequencing tech portfolio and rising system adoption highlight growth momentum despite ongoing purchasing cycle challenges.

The latest trading day saw Pacific Biosciences of California (PACB) settling at $1.26, representing a -6.67% change from its previous close.

PACB wins Basecamp deal to power Trillion Gene Atlas using HiFi sequencing, advancing AI-driven drug discovery with high-accuracy genomic data.

Pacific Biosciences (PACB) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

PacBio's Revio system and SPRQ-Nx chemistry to enable an order-of-magnitude expansion of HiFi metagenomic sequencing for scaling AI-designed therapeutics PacBio's Revio system and SPRQ-Nx chemistry to enable an order-of-magnitude expansion of HiFi metagenomic sequencing for scaling AI-designed therapeutics

Proven experience in leveraging AI in biology will strengthen the board of directors as PacBio develops data tools to maximize the power of HiFi sequencing Proven experience in leveraging AI in biology will strengthen the board of directors as PacBio develops data tools to maximize the power of HiFi sequencing

PACB teams with DNAstack to launch a global HiFi genome network, linking 10,000+ sequences to boost rare disease research without moving data.

Collaboration powers secure international data sharing through the HiFi Solves Global Consortium Collaboration powers secure international data sharing through the HiFi Solves Global Consortium